Multiple Myeloma Treatments for the Transplant-Eligible and Non–Transplant-Eligible Patient

Mantle cell lymphoma (MCL) and peripheral T-cell lymphomas (PTCL) are rare subtypes of non-Hodgkin’s lymphoma that together comprise <5% of all cases of NHL in adults. Both diseases are associated with poor outcomes with standard front line NLH chemotherapy. Additionally, investigations into new therapies for MCL and PTCL have been historically difficult due to their rarity.

Grand Rounds in Hematology: How the Experts Treat Hematologic Malignancies in 2012

According to the American Cancer Society, it was estimated in 2011 there were 44,600 cases of leukemia, 66,360 cases of non-Hodgkin lymphoma, 8,830 cases of Hodgkin lymphoma, and 20,520 cases of myeloma diagnosed for the first time. In addition, the Leukemia and Lymphoma Society estimates that one person is diagnosed with a blood cancer approximately every four minutes in the U.S. The outcome for patients with hematologic malignancies has dramatically changed with the use of novel therapies.

Grand Rounds in Hematology: Volume 3, Issue 2

How The Experts Treat Hematologic Malignancies: A Roadmap to Treatment   OVERVIEW By the end of 2009, it was estimated that 65,000 people were living with multiple myeloma, 675,670 with lymphoma, and 290,015 with or in remission from some form of leukemia. Given the...

How the Experts Treat Cancer Module 1 (Myeloma)

Presentation Agenda Improving Outcomes in Multiple Myeloma Amrita Y. Krishnan, MD, FACP Director, Multiple Myeloma Program Department of Hematology/HCT City of Hope National Medical Center Duarte, CA Presentation and Discussion Myo Htut, MD BMT Fellow Department of...